Updated on 15 June 2016
Singapore: The Milner Therapeutics Consortium, the outreach program of England's Milner Therapeutics Institute, has announced Shionogi as a new partner joining the consortium.
Dr Takeshi Shiota, Senior Vice President, Pharmaceutical Research Division at Shionogi has joined the consortium's Innovation Board along with representatives from other consortium members Astex, AstraZeneca, GlaxoSmithKline, University of Cambridge, Babraham Institute and Sanger Institute.
The Milner Therapeutics Consortium was established in 2015 and the company says it acts as a ‘match-making' service between pharmaceutical companies and researchers in Cambridge. The consortium brings together the drug development capability of pharmaceutical companies with the know-how of entire academic institutions in Cambridge and has been specifically modeled to facilitate the speedy exchange of resources and information between partners through a pre-signed agreement. Company partners are able to work individually with academics or through joint activities in order to accelerate drug development.
The consortium's Innovation Board includes companies and academic partners and is responsible for overseeing the strategic direction, collective research funding and collaborative activities. In the last two months, 18 companies have become affiliated with the Milner Therapeutics Institute including Charles River Laboratories.
Commenting on the announcement, Prof Tony Kouzarides, Founder and Director of the Milner Therapeutics Institute and Consortium said, "We are building the foundations for a world-leading hub in Cambridge around the Milner Therapeutics Institute. We are very pleased that Shionogi has become a consortium partner demonstrating that the consortium works on a truly global scale and that companies can collaborate with scientists in Cambridge even if they do not have research sites in the UK. Momentum is gathering around the Institute as eighteen companies, including Charles River Laboratories, have become affiliated in the last few weeks and we have interest from many more."